1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NEI Research for Low Vision and Blindness Accessibility Tools (R61/R33 Clinical Trial Optional) is sponsored by National Institutes of Health (NIH). This Notice of Funding Opportunity (NOFO) aims to stimulate translational efforts in developing and implementing accessibility devices or interventions that apply new technologies to address challenges faced by individuals living with visual impairment.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
## View Grant Opportunity NEI Research for Low Vision and Blindness Accessibility Tools (R61/R33 Clinical Trial Optional) Department of Health and Human Services National Institutes of Health Document Type:Grants Notice Funding Opportunity Number:RFA-EY-24-003 Funding Opportunity Title:NEI Research for Low Vision and Blindness Accessibility Tools (R61/R33 Clinical Trial Optional) Opportunity Category:Discretionary Opportunity Category Explanation: Funding Instrument Type:Grant Category of Funding Activity:Health Expected Number of Awards: Assistance Listings:93.
867 -- Vision Research Cost Sharing or Matching Requirement:No Last Updated Date:May 17, 2024 Original Closing Date for Applications:Aug 13, 2024 Current Closing Date for Applications:Aug 13, 2024 Archive Date:Sep 18, 2024 Estimated Total Program Funding: Eligible Applicants:Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) For profit organizations other than small businesses Public and State controlled institutions of higher education City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Independent school districts Others (see text field entitled "Additional Information on Eligibility" for clarification) Private institutions of higher education Public housing authorities/Indian housing authorities Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Additional Information on Eligibility:Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
## Additional Information Agency Name:National Institutes of Health Description:The purpose of this Notice of Funding Opportunity (NOFO) is to stimulate translational efforts in developing and implementing accessibility devices or interventions that apply new technologies to address challenges faced by individuals living with visual impairment.
Critical elements of applications include a clear set of milestones that support development and testing of the tool, device, or intervention proposed; multidisciplinary and collaborative teams that include individuals with lived experience; and a tractable dissemination plan.
The overall goal of the program is to push the boundaries of innovation in technology development to address accessibility needs of individuals with visual impairment and create resources that will be made available to the community. This NOFO uses a milestone driven and phased mechanism of award.
Initial technology development and feasibility activities (R61 phase) may transition to expanded research support (R33 phase) for validation, larger-scale feasibility, and effectiveness studies. All applications must address both R61 and R33 phases. Link to Additional Information:https://grants.
nih. gov/grants/guide/rfa-files/RFA-EY-24-003. html Grantor Contact Information:If you have difficulty accessing the full announcement electronically, please contact:
According to the current listing, eligibility includes: Non-domestic (non-U. S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U. S.) components of U. S. Organizations are not eligible to apply. Confirm the full requirements in the official notice before applying.
NEI Research for Low Vision and Blindness Accessibility Tools (R61/R33 Clinical Trial Optional) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article